Sanofi pasteur, 2 avenue Pont Pasteur F-69367 Lyon cedex 07 France.
BMC Med Res Methodol. 2010 Mar 8;10:18. doi: 10.1186/1471-2288-10-18.
Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.
We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.
A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.
Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
通过血凝抑制(HI)测定法测定的针对血凝素的抗体对于预防流感感染的保护性免疫至关重要。通常认为 HI 滴度为 1:40 与易感人群中流感感染风险降低 50%相对应,但对 HI 滴度与保护效力之间的关联进行进一步量化的尝试有限。
我们使用荟萃分析方法提出了一个模型,该模型估计了在任何 HI 滴度水平下针对流感的临床保护水平。原始数据来自系统文献综述,该综述确定了 15 项研究,共涉及 5899 名成年受试者和 1304 例流感病例,这些病例具有 HI 滴度的区间 censored 信息。使用贝叶斯推理,考虑到可用信息中的随机效应和 censoring,估计了 HI 滴度与临床保护之间的关系参数。
在所有测试模型中,均观察到 HI 滴度与针对流感的临床保护之间存在显著的正相关关系。无论病毒株(A 型或 B 型)的类型如何,以及个体的疫苗接种状态如何,这种关系均被发现是相似的。
尽管不应忽视所使用数据的局限性,但本分析中得出的关系为仅提供免疫原性数据时预测灭活流感疫苗的效力提供了一种方法。该关系还可用于根据其免疫学特征比较不同流感疫苗的效力。